OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology

Educational Programs

Atopic Dermatitis & Psoriasis

2025

This three-part educational series explores the OX40 pathway and its potential in treating pediatric inflammatory skin diseases. The webinar features leading experts discussing the science behind OX40 and OX40L, emerging research, and therapeutic implications. Follow-up podcasts extend the conversation—first, with a look toward the future of OX40 therapies and the evolving concept of remission in atopic dermatitis, and then with a patient-centered dialogue highlighting how advocacy leaders are helping shape research and communication around new treatments.

This episode originally aired in August 2025. Since then, roles on PeDRA committees and positions at institutions or organizations may have changed.

Special thanks to Amgen, Sanofi, and Astria Therapeutics for their support of this independent medical education program. PeDRA is solely responsible for all program content and the selection of all presenters, authors, moderators, and faculty.

Part One

OX40: Innovative Insights and Emerging Clinical Trial Data
This engaging and informative webinar explores the role of OX40 and OX40L in pediatric dermatology. OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology brings together experts, Dr. Larry Eichenfield, Dr. Eric Simpson, and Dr. Joy Wan, to discuss emerging research, mechanisms of action, and the implications of targeting the OX40 pathway for treating chronic inflammatory skin diseases in children.

Part Two

Innovative Insights Discussion
Following the OX40 webinar, Dr. Eichenfield, Dr. Simpson, and Dr. Wan continue the conversation with a look ahead at the future of OX40 therapies and their potential to change the course of disease. They also unpack the complex concept of remission in atopic dermatitis—what it means, how it’s defined, and whether it’s truly achievable.

Lawrence Eichenfield, MD

Program Presenter

Eric Simpson, MD

Program Presenter

Joy Wan, MD

Program Moderator

Part Three

Patient-Focused Discussion
In our final episode, Dr. Joy Wan moderates a thoughtful discussion with two leaders from the patient advocacy community. Wendy Smith Begolka, MBS, Chief Program and Mission Officer at the National Eczema Association, and Korey Capozza, MPH, Founder and Executive Director of Global Parents for Eczema Research, share their perspectives on incorporating patient priorities into clinical trials and effectively communicating with patients about new and emerging treatments.